The introduction of drug-coated balloon (DCB) catheters represented an important forward step in the treatment of patients with obstructive coronary artery disease.(1)The first devices for coronary use received regulatory approval in Europe in 2009. Since that time, adoption in clinical practice has increased gradually, initially for the indication of treatment for in-stentrestenosis and subsequently for the treatment of patients with de novo lesions.(2)
Funding
Abbott Vascular
Biosensors
Boston Scientific and Translumina
History
Comments
The original article is available at https://www.sciencedirect.com/
Published Citation
Byrne RA, Durand R. Sirolimus-coated balloon angioplasty for coronary artery disease: one step forward, two steps back. JACC Cardiovasc Interv. 2023;16(23):2897-2899.